GlassScriptPhysician profile
Joseph Pratt
NPI 1417953233
$10,002.45
in general payments reported to CMS, 2019-2025
58 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $1,186 · 2021: $1,856 · 2022: $1,469 · 2023: $1,076 · 2024: $951 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,578 · Education: $32.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.66 |
| Education | $32.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.28 | 2020-2025 | |
| Pfizer INC. | $822.93 | 2019-2025 | |
| Amgen INC. | $625.37 | 2019-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $535.96 | 2019-2023 | Xarelto |
| Alpha Cognition USA, INC. | $443.04 | 2025 | Zunveyl |
| Glaxosmithkline, LLC. | $435.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.28 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $376.28 | 2019-2023 | Trintellix |
| Allergan, INC. | $368.58 | 2019-2020 | |
| Astellas Pharma US INC | $339.55 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $316.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $282.94 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $261.45 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.05 | 2019-2023 | Ofev |
| Amarin Pharma, INC. | $220.76 | 2020-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.